DexCom (NASDAQ:DXCM) Stock Jumps 5.3% on Earnings Beat

Key Points

• DexCom shares rose 5.3% after the company reported quarterly earnings of $0.73 per share, beating the $0.68 consensus estimate, while revenue reached $1.34 billion and increased 11.1% year over year.
• Management raised its 2026 sales outlook and authorized a $1 billion share-repurchase program, signaling confidence in continued demand for its continuous glucose monitoring products.
• Analysts maintain a broadly positive view, with the stock carrying a consensus “Buy” rating and a $92.57 price target; scheduled insider sales remain a modest sentiment risk.

Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) were up 5.3% during mid-day trading on Friday following a better than expected earnings announcement. The stock traded as high as $85.25 and last traded at $84.1520. Approximately 1,425,039 shares traded hands during trading, a decline of 71% from the average daily volume of 4,995,772 shares. The stock had previously closed at $79.93.

The medical device company reported $0.73 EPS for the quarter, beating analysts' consensus estimates of $0.68 by $0.05. The company had revenue of $1.34 billion during the quarter, compared to analysts' expectations of $1.33 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm's revenue was up 11.1% compared to the same quarter last year. During the same period last year, the business posted $0.61 earnings per share.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Strong third-quarter results: DexCom reported adjusted earnings of $0.73 per share, exceeding consensus estimates of approximately $0.66–$0.68, while revenue of $1.34 billion topped expectations by about $10 million. Revenue increased roughly 11% year over year, and operating profit rose sharply, highlighting continued margin improvement. DexCom Third-Quarter Earnings Results
• Positive Sentiment: Higher outlook: Management raised its 2026 sales guidance, reinforcing investor confidence that demand for DexCom’s continuous glucose monitoring products remains resilient. DexCom Raises Sales Guidance
• Positive Sentiment: $1 billion buyback: DexCom authorized an equity repurchase program worth up to $1.0 billion. The plan may support earnings per share and signals that management views the company’s shares as an attractive use of capital. DexCom Announces $1 Billion Buyback
• Positive Sentiment: Product expansion: DexCom plans to launch its G7 15-day continuous glucose monitoring system in Canada in November, expanding the availability of its newest platform. DexCom G7 15-Day Canada Launch
• Negative Sentiment: Insider selling: Executive Vice President Sadie Stern sold 2,565 shares for approximately $202,000 under a pre-arranged Rule 10b5-1 plan. The scheduled nature of the transaction reduces its significance, but continued insider sales may temper sentiment. DexCom Insider Sale

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on DXCM shares. Weiss Ratings upgraded DexCom from a "hold (c)" rating to a "hold (c+)" rating in a research report on Tuesday, October 6th. Argus increased their target price on DexCom from $86.00 to $96.00 and gave the company a "buy" rating in a research report on Tuesday, August 4th. Royal Bank Of Canada restated an "outperform" rating and set a $105.00 price target (up from $90.00) on shares of DexCom in a research report on Thursday, October 1st. TD Cowen reaffirmed a "buy" rating and set a $95.00 target price on shares of DexCom in a report on Friday, September 18th. Finally, Barclays raised DexCom to a "strong-buy" rating in a research note on Wednesday, October 7th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $92.57.

Insider Activity at DexCom

In related news, EVP Jereme M. Sylvain sold 3,638 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $83.27, for a total value of $302,936.26. Following the transaction, the executive vice president owned 146,828 shares of the company's stock, valued at $12,226,367.56. This represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of the company's stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares of the company's stock, valued at $4,168,052.64. This represents a 3.93% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 24,822 shares of company stock worth $2,090,833 over the last ninety days. 0.28% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Latitude Advisors LLC acquired a new stake in shares of DexCom in the third quarter valued at approximately $32,000. Hilton Head Capital Partners LLC lifted its stake in shares of DexCom by 242.3% in the 3rd quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company's stock valued at $33,000 after purchasing an additional 269 shares in the last quarter. Ascentis Independent Advisors purchased a new stake in DexCom during the first quarter worth approximately $25,000. Elevation Wealth Partners LLC boosted its position in shares of DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company's stock worth $35,000 after buying an additional 152 shares during the period. Finally, GK Wealth Management LLC purchased a new stake in shares of DexCom during the third quarter valued at approximately $35,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

DexCom Trading Up 3.8%

The business's 50-day simple moving average is $85.98 and its two-hundred day simple moving average is $74.60. The company has a market capitalization of $31.30 billion, a PE ratio of 32.81, a PEG ratio of 1.32 and a beta of 1.48. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom Company Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company's product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.